|Title:||Cancer as an infectious disease: A different treatment alternative using a combination of tigecycline and pyrvinium pamoate - An example of breast cancer||Authors:||Huang, Shu-Wei
|Keywords:||Breast cancer; Combination therapy; Pyrvinium pamoate; Tigecycline||Issue Date:||Feb-2022||Publisher:||ELSEVIER TAIWAN||Journal Volume:||55||Journal Issue:||1||Start page/Pages:||51||Source:||Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi||Abstract:||
Tigecycline is an antibiotic that well tolerated for treating complicated infections. It has received attention as an anti-cancer agent and expected to solve two major obstacles, sides effects that accompany chemotherapy and drug resistance, in the breast cancer treatment. However, previous studies reported that the levels in the blood are typically low of tigecycline, so higher doses are needed to treat cancer, that may increase the risk of side effects. To achieve better anti-cancer effects for tigecycline, we need to find a novel adjunct agent.
|Appears in Collections:||醫學工程學研究所|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.